- Home
- ASND
ASND
Ascendis Pharma A/S
as 07-26-2024 4:00pm EST
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
| Founded: | 2006 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.8B | IPO Year: | 2015 |
| Target Price: | $186.33 | AVG Volume (30 days): | 263.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $85.29 - $161.00 | Next Earning Date: | 09-03-2024 |
| Revenue: | $357,633,696 | Revenue Growth: | 322.18% |
| Revenue Growth (this year): | 67.94% | Revenue Growth (next year): | 63.49% |
Latest Ascendis Pharma A/S News
ASND Breaking Stock News: Dive into ASND Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year
TipRanks
19 days ago
2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect
MT Newswires
21 days ago
Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada
Pharmaceutical Technology
22 days ago
Pendopharm and Ascendis to distribute hypoparathyroidism treatment
CNW Group
22 days ago
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada
MT Newswires
a month ago
TD Cowen Upgrades Ascendis Pharma to Buy Rating With $175 Price Target
GlobeNewswire
a month ago
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
Insider Monkey
a month ago
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
Compare ASND vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ASND Ascendis Pharma A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.